Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Fennell DA, King A, Mohammed S, Greystoke A, et al. Lancet Oncol 2022;23:374-381.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fennell DA, King A, Mohammed S, Greystoke A, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol 2022;23:374-381.
PMID: 35157829